RxDoctor Payments Data

Steven Marshak, MD

Internal Medicine · Rockville, MDNPI 1730110305

Payments from drug & device makers

$5,802in general payments, 2019–2025

Across 289 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$953
  • AbbVie$822
  • Ironshore Pharmaceuticals Inc.$412
  • Takeda Pharmaceuticals U.S.A., Inc.$400
  • Pfizer$375
  • Lilly USA, LLC$319
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,802100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,802 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$153,890
Medicare patients
438
Services billed
1,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$21,213
XareltoRivaroxaban12$10,169
SynthroidLevothyroxine Sodium79$7,981
OxycontinOxycodone Hcl12$6,397
Atorvastatin Calcium290$3,355
Tamsulosin Hcl88$2,396
Levothyroxine Sodium196$2,361
Rosuvastatin Calcium152$2,144
Sertraline Hcl41$2,085
Amlodipine Besylate191$1,786
Losartan Potassium132$1,779
Ezetimibe20$1,513
Bupropion XlBupropion Hcl23$1,494
Metoprolol Succinate65$1,346
Azelastine Hcl28$1,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$953$21,21312 claims
AbbVieSynthroid$822$7,98179 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$34$2,361196 claims
Almatica Pharma LLCSertraline Hcl$19$2,08541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →